Figures & data
Figure 1. Incidences and severity of solicited systemic or local AEs within 7 days following each of the 2 doses of either placebo or the Moderna COVID-19 vaccine.
![Figure 1. Incidences and severity of solicited systemic or local AEs within 7 days following each of the 2 doses of either placebo or the Moderna COVID-19 vaccine.](/cms/asset/90aa434e-2386-4525-9d43-711fe0c3dee2/ierv_a_2262571_f0001_oc.jpg)
Table 1. Incidences of solicited systemic adverse events within 7 days following vaccination with the recombinant zoster vaccine (RZV) or placebo.
Table 2. Incidences of solicited and unsolicited systemic adverse events within 7 days of the recombinant zoster vaccine (RZV) or placebo.
Table 3. Estimating adverse event (AE) incidence after co-administration vs incidence after single administration of each vaccine, in the absence of enhancement due to co-administration.
Figure 2. Upper limit of the one-sided 95% CI of the true incidence of an event according to the number of participants in the absence of reported cases.
![Figure 2. Upper limit of the one-sided 95% CI of the true incidence of an event according to the number of participants in the absence of reported cases.](/cms/asset/eeb65e52-4f6a-429d-9888-5a38962e8afa/ierv_a_2262571_f0002_oc.jpg)
Figure 3. Width of the two-sided 95% confidence interval of the true incidence of an event according to the number of participants and for different observed incidences.
![Figure 3. Width of the two-sided 95% confidence interval of the true incidence of an event according to the number of participants and for different observed incidences.](/cms/asset/d89f81e6-e756-45f4-b033-f53ec7ffb873/ierv_a_2262571_f0003_oc.jpg)
Table 4. Steps to consider during study design, analysis and when updating the label with AE data.